anti-EGFR/LGR5 bispecific antibody MCLA-158

{
  "id": "MLC-T-ONC-010613",
  "term": "anti-EGFR/LGR5 bispecific antibody MCLA-158",
  "field": "Oncology and biomedicine",
  "definition": "An immunoglobulin G1 (IgG1) bispecific antibody targeting both epidermal growth factor receptor (EGFR; HER1; ErbB1) and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), with potential antineoplastic activity. Upon administration, anti-EGFR/LGR5 bispecific antibody MCLA-158 simultaneously targets and binds to both EGFR and LGR5, thereby inhibiting the activation of both EGFR- and LGR5-mediated signaling pathways. This results in the inhibition of tumor cell proliferation. EGFR, a receptor tyrosine kinase (RTK) upregulated and/or mutated in a variety of tumor cell types, plays an important role in tumor cell proliferation. LGR5, a member of the Wnt signaling pathway, is a cancer stem cell (CSC) receptor overexpressed on certain cancer cells; it plays a key role in CSC proliferation and survival.",
  "synonyms": [
    "anti-EGFR/anti-LGR5 bispecific antibody MCLA-158",
    "EGFR x LGR5 bispecific antibody MCLA-158"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-egfr-lgr5-bispecific-antibody-mcla-158/"
}